Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the time taken to decide on patient access scheme applications for drugs through the Cancer Drugs Fund.

Within the framework set out in the 2014 Pharmaceutical Price Regulation Scheme, a Patient Access Scheme (PAS) can be proposed by a pharmaceutical company and agreed by the Department to improve the cost-effectiveness of a medicine as part of a National Institute for Health and Care Excellence (NICE) technology appraisal.

A PAS proposal can only be submitted for a medicine that is available through the Cancer Drugs Fund if that product is also scheduled for appraisal or review by NICE and no assessment has been of the time taken to consider any such PAS proposals.